Condition 1: Depression. Condition 2: Anxiety. Mild depressive episode, moderate depressive episode, recurrent depressive disorder current episode mild, recurrent depressive disorder current episode moderate Other anxiety disorders
Conditions
Interventions
Intervention 1: One 400 mg oral capsule from Nepeta menthoides aerial parts freeze-dried water extract (extract concentration, 10%), twice daily (one in morning half hour before breakfast and one at
Treatment - Drugs
One 400 mg oral capsule from Nepeta menthoides aerial parts freeze-dried water extract (extract concentration, 10%), twice daily (one in morning half hour before breakfast and one at night 1-2 hour b
Serteraline (Sertrabiol manufactured by Bakhtar Bioshimi Co.) , 50 mg in each capsule, one capsule twice daily
Sponsors
Vice chancellor for research, Shiraz University of Medical Science
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Adult outpatients between 18-65 referring to psychiatry clinic of Shiraz medical university; meet Becks depression inventory (BDI-II) and DSM-V-TR criteria for mild to moderate major depression; confirmation of the diagnosis by at least two psychiatrist; and informed consent. Exclusion criteria: Having other conditions assuming depression such as: hypothyroidism, psychiatric disorders except for mild to moderate major depression, mental disorders i.e. dementia or mental retardation; allergy to Nepeta Menthoides or other mentheae family (Lamiaceaes); substance dependency; pregnancy; suicidal thinking or needing to electroconvulsive therapy; not having informed consent
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of depression. Timepoint: At the base line,2nd week, 4th week after beginning of intervention and then in 6th week (2 weeks after the end of intervention). Method of measurement: Beck depression inventory(BDI-II) score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects profile. Timepoint: At the base line, 2nd week, 4th week after beginning of intervention and then in 6th week (2 weeks after the end of intervention). Method of measurement: Clinical interview and physical examination and list in a table.;Severity of anxiety. Timepoint: At the base line, 2nd week, 4th week after beginning of intervention and then in6th week (2 weeks after the end of intervention). Method of measurement: Beck anxiety inventory (BAI) score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSepideh Koloury
Shiraz University of Medical Science
Outcome results
None listed